Rein Therapeutics funds LTI-03 lung-fibrosis trial beyond 2027 readout as enrolment hits 75%
The small inhaled-drug developer says its $36.5 million cash balance should outlast the expected 2027 results from its Phase 2 RENEW study, as an early data look stays inconclusive by design.
Rein Therapeutics said on 16 November 2026 that it has about $36.5 million in cash, measured at the end of the third quarter, and expects that to cover operations into the first quarter of 2028. The company expects the main results of its Phase 2 RENEW study of inhaled LTI-03 in idiopathic pulmonary fibrosis (IPF) in 2027, so on its own projection the funding extends past that milestone.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Rein Therapeutics, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.